rs10195252 — GRB14/COBLL1
Intergenic variant between GRB14 and COBLL1 that acts as an eQTL for GRB14 in adipose tissue, shifting body fat toward peripheral (hip and limb) versus central (visceral) deposition
Details
- Gene
- GRB14/COBLL1
- Chromosome
- 2
- Risk allele
- C
- Consequence
- Regulatory
- Inheritance
- Additive
- Clinical
- Risk Factor
- Evidence
- Strong
- Chip coverage
- v3 v4 v5
Population Frequency
Ancestry Frequencies
Related SNPs
Category
Nutrition & MetabolismSee your personal result for GRB14/COBLL1
Upload your DNA data to find out which genotype you carry and what it means for you.
Upload your DNA dataWorks with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.
The Fat Geography Gene: How rs10195252 Routes Fat to Limbs or Viscera
Where your body stores fat matters as much as how much fat you carry. Two people with identical BMI can have entirely different metabolic risk profiles depending on whether their excess fat accumulates around their organs (visceral) or in their hips, thighs, and legs (peripheral). The rs10195252 variant in the intergenic region between GRB14 and COBLL1 on chromosome 2 is one of the most replicated genetic determinants of this fat routing — and its effects are substantially stronger in women than men.
GRB14 (Growth Factor Receptor-Bound Protein 14) is an adaptor protein
that acts as a braking mechanism on the insulin receptor11 adaptor protein
that acts as a braking mechanism on the insulin receptor
GRB14 binds to
the activated insulin receptor and inserts its BPS domain as a
pseudosubstrate inhibitor, blocking downstream signaling.
Higher GRB14 expression in adipose tissue means weaker insulin signaling
in that depot, which in turn affects how efficiently fat is stored and
mobilized there. COBLL1 (Cordon-Bleu WH2 Repeat Protein-Like 1) is the
neighboring gene and shares part of the regulatory landscape; it too is
associated with leptin, central obesity, and fasting insulin.
The Mechanism
rs10195252 sits in the intergenic region between GRB14 and COBLL1 and
functions as an expression quantitative trait locus (eQTL)22 expression quantitative trait locus (eQTL)
An eQTL is
a genetic variant that controls how much mRNA a nearby gene produces,
without changing the protein's amino acid sequence
for GRB14 in adipose tissue. The T allele drives higher GRB14 expression,
particularly in visceral adipose tissue, which suppresses insulin signaling
in the belly and promotes a pattern where fat moves toward central
compartments and away from peripheral depots. The C allele is associated
with lower GRB14 expression, allowing more robust insulin signaling in
visceral fat — which has the paradoxical effect of facilitating fat storage
in peripheral depots (hips, thighs, lower limbs) while leaving central fat
accumulation less hormonally supported.
This means the C allele shifts the body's default fat routing toward
gynoid (peripheral/lower-body) distribution33 gynoid (peripheral/lower-body) distribution
Named for the pattern more
common in women; associated with higher hip-to-waist ratio and fat
deposition in thighs, buttocks, and lower legs.
The T allele does the opposite — it shifts fat toward the android (central,
visceral) pattern. This explains why the T allele increases waist-hip ratio
(WHR) while the C allele decreases it.
The Evidence
The foundational study is the 2010 GIANT consortium meta-GWAS of
77,167 individuals44 meta-GWAS of
77,167 individuals
Analysis across 32 separate genome-wide association
studies; rs10195252 reached p = 5.9 × 10⁻¹⁵ for WHR adjusted for BMI, which identified rs10195252
as one of 13 new loci for waist-hip ratio. The GRB14 locus showed marked
sexual dimorphism — the effect was substantially stronger in women than men
— consistent with estrogen's role in modulating insulin signaling in adipose
depots. A subsequent larger meta-analysis of 224,459 individuals55 larger meta-analysis of 224,459 individuals
Shungin et al. 2015; linked adipose tissue biology and insulin signaling
directly to fat distribution genetics
confirmed the locus among those most strongly linking adipose insulin
biology to body fat distribution.
A key functional study by Gruber et al. 202266 Gruber et al. 2022
n = 2,860 subjects with
metabolic phenotypes; 560 subjects with adipose tissue gene expression
measurements demonstrated
that the T allele at rs10195252 was significantly associated with increased
GRB14 mRNA in visceral adipose tissue and that this visceral GRB14
expression fully mediated the association between rs10195252 and HbA1c —
connecting the genetic variant to real-world glucose regulation through an
adipose tissue molecular pathway. Carriers of the T allele also showed
higher triglycerides, higher fasting plasma glucose, and lower HDL
cholesterol.
The connection to lipedema — a condition of disproportionate lower-body
and limb fat accumulation predominantly in women — was established by a
UK Biobank GWAS of 24,450 cases77 UK Biobank GWAS of 24,450 cases
Lörcher et al. 2022; GRB14/COBLL1
locus replicated in independent clinical lipedema cohort (130 cases);
p = 2.3 × 10⁻³. The locus
was associated specifically with leg fat percentage, independently of hip
circumference — meaning the effect is not simply driven by large hips but
by fat throughout the lower limbs. This finding directly implicates
C-allele-driven peripheral fat routing in lipedema pathophysiology.
Practical Implications
For individuals carrying one or two copies of the C allele, the body's fat storage preference runs toward the lower limbs and hips. This does not cause lipedema on its own — lipedema is multifactorial — but it represents a significant component of the genetic predisposition. The insulin signaling pattern in visceral adipose may be more robust (lower GRB14 expression), but peripheral fat depots respond to insulin more readily, making them preferential storage sites.
Two actionable implications follow: First, interventions that transiently lower insulin (reducing carbohydrate intake, time-restricted eating) can partially redirect fat mobilization away from the peripheral depots where GRB14 expression is lower and insulin sensitivity is higher. Second, monitoring waist-hip ratio and lower-limb circumference provides more informative tracking data than scale weight alone, since weight loss may unevenly reduce peripheral fat stores.
The T-allele pattern (higher central fat tendency, higher GRB14 visceral expression) carries its own concern: association with higher HbA1c, triglycerides, and fasting insulin suggests elevated cardiometabolic risk independent of BMI.
Interactions
The GRB14/COBLL1 locus interacts with other fat distribution variants on
chromosome 2 and overlapping GWAS signals. The nearby rs6738627 in
COBLL188 rs6738627 in
COBLL1
A second index SNP at this locus with partially independent
effects on body fat percentage and leptin levels
is separately associated with body fat percentage independently of BMI.
Both rs10195252 and rs6738627 show overlapping metabolic associations
(triglycerides, glucose, leptin), suggesting the entire locus regulates
adipose tissue insulin signaling and fat partitioning as a functional unit.
Supervisor note — candidate compound interaction: The C allele at rs10195252 (peripheral fat routing) and the A allele at rs9939609 (FTO, increased adiposity/appetite) combine in a pattern where both fat volume and fat routing tilt unfavorably — higher total fat mass directed preferentially to limbs and lower body. Published evidence for this specific combination is not available, but both loci are independently established for fat distribution traits and the combined phenotype (excess peripheral fat mass) is clinically meaningful for lipedema risk assessment. A compound monitoring recommendation covering both variants would be appropriate if supported by future data.
Nutrient Interactions
Genotype Interpretations
What each possible genotype means for this variant:
Common genotype associated with relatively more central fat distribution and standard WHR
The TT genotype sits at the central-fat end of the rs10195252 spectrum. In the GIANT consortium meta-GWAS (n = 77,167), the T allele was the WHR-increasing allele, with association p = 5.9 × 10⁻¹⁵ for WHR adjusted for BMI — one of the strongest fat distribution signals in the human genome. In functional studies, TT carriers' visceral adipose tissue expresses higher levels of GRB14 mRNA, which inhibits insulin receptor signaling in that depot. The metabolic consequence is that visceral fat is less insulin-sensitive, making it less of a preferred fat storage site and directing caloric surplus toward other compartments or leaving it circulating as triglycerides.
Gruber et al. (2022) showed that in a cohort of 2,860 subjects, rs10195252 was associated with HbA1c, and this association was fully mediated by visceral GRB14 expression — meaning the T allele's metabolic effects run through the adipose GRB14 pathway. Triglycerides, fasting glucose, and leptin were also elevated in T-allele carriers. The lipedema GWAS found that the equivalent allele at this locus was not associated with lipedema risk, consistent with the T allele's peripheral-fat-sparing effect.
One C allele shifts fat distribution moderately toward peripheral (hip, thigh, limb) deposition
Heterozygous CT carriers express intermediate levels of GRB14 in adipose tissue compared to TT and CC individuals. This translates to a moderately gynoid (pear-shaped) fat distribution tendency, with fat somewhat preferentially routed to hips, thighs, and lower legs over visceral compartments.
Population data show the C allele is associated with lower WHR, reduced visceral fat area, and a more peripheral fat pattern. In the lipedema GWAS (Lörcher et al. 2022), the locus was associated with leg fat percentage specifically and independently of hip circumference, suggesting the effect runs through lower-limb fat deposition rather than merely broader hip circumference. For CT heterozygotes, the practical risk is approximately half that of CC homozygotes for peripheral fat accumulation.
Metabolically, CT carriers are closer to the favorable metabolic profile (lower visceral fat, potentially lower HbA1c and triglycerides) than TT carriers, though the relationship is additive rather than dominant.
Two C alleles strongly shift fat distribution toward peripheral (limb and hip) deposition, linked to lipedema susceptibility
CC homozygotes sit at the peripheral end of the GRB14-mediated fat routing spectrum. Lower GRB14 expression in adipose tissue means insulin signaling runs less inhibited in peripheral fat depots, making them more insulin-responsive and thus more metabolically active fat storage sites. This gynoid (lower-body) fat pattern is associated with a lower waist-hip ratio, which carries cardiovascular benefits compared to central adiposity — lower visceral fat, typically more favorable lipid profiles. However, when the peripheral fat routing becomes extreme, it characterizes lipedema: disproportionate, painful fat accumulation in the lower limbs that is non-pitting and resistant to caloric restriction.
The Lörcher et al. (2022) lipedema GWAS identified the GRB14/COBLL1 locus (proxied by nearby rs1128249, which is in strong LD with rs10195252) in a discovery cohort of 24,450 cases vs 165,227 controls, with successful replication in 130 clinically diagnosed lipedema cases. Critically, the association was with leg fat percentage specifically and independently of hip circumference — implicating fat throughout the lower limbs rather than simply broad hips. This is the hallmark of lipedema pathology.
The CC genotype is substantially more common in populations of African descent (C allele frequency ~0.73), where the gynoid fat pattern is well documented to be more prevalent. This may contribute to the underdiagnosis of lipedema in non-European populations where the condition has historically been studied less.
From a metabolic standpoint, CC individuals may have somewhat more favorable central/visceral metabolic markers (lower HbA1c, lower triglycerides) compared to TT carriers, but the peripheral fat burden itself carries its own clinical considerations — especially in the context of lymphatic stress on lower limbs.
Key References
Heid et al. 2010 (GIANT) — meta-GWAS identifying rs10195252 at GRB14 as one of 13 new WHR loci, with sex-dimorphic effect stronger in women; p = 5.9 × 10⁻¹⁵
Shungin et al. 2015 (GIANT) — large meta-analysis of 224,459 individuals confirming GRB14/COBLL1 among loci linking adipose and insulin biology to fat distribution
Gruber et al. 2022 — rs10195252 T-allele associated with increased visceral GRB14 expression and HbA1c, mediated through adipose GRB14 mRNA levels
Gutsmann et al. 2013 — depot-specific GRB14 mRNA expression in visceral vs. subcutaneous adipose; rs10195252 nominally associated with subcutaneous GRB14 expression
Lörcher et al. 2022 — GRB14/COBLL1 locus (rs1128249) replicated in lipedema GWAS; associated with leg fat percentage independently of hip circumference; OR = 0.92
Cariou et al. 2004 — increased GRB14 adipose expression in ob/ob mice and type 2 diabetic humans; GRB14 directly inhibits insulin receptor tyrosine kinase
Morley-Smith et al. 2020 — GRB14 inhibition improves glucose homeostasis in diet-induced obese mice without cardiac toxicity, establishing GRB14 as a therapeutic target